Exam 2: NU664D / NU 664D (Latest
Update ) Primary Care
Adult Woman I | Questions &
Answers | Grade A | 100% Correct -
Regis
Question:
Lysteda (TXA) dose
Answer:
650mg 2 tabs BID x 5 days during menses
Question:
Lysteda when to prescribe
Answer:
when other options have been unsuccessful to tx menorrhagia in patients who
are not at high risk for thrombosis
,Question:
lysteda mechanism of action
Answer:
antifibrinolytic effect by blocking lysine bindings sites on plasminogen to
prevent fibrin degradation
Question:
menorrhagia: clinical manifestations
Answer:
bleeding more than 80ml/cycle, or cycle lasting longer than 7 days
Question:
menorrhagia: differential dx
Answer:
pregnancy, cervical abnormalities, uterine abnormalities, endometriosis,
medications, endocrine, foreign body
,Question:
menorrhagia: diagnostic wu
Answer:
UPT, cbc, std, pap, endometrial biopsy
depending on sxs
TSH
PTT, PT
Factor VIII
Von Willebrand
DHEA-S
testosterone
US
hysteroscopy
prolactin
Question:
menorrhagia: endometrial biopsy
Answer:
for all women > 45 OR AUB and other associated risk factors (unopposed
estrogen exposure, failed medical management of bleeding)
, Question:
menorrhagia: tx for hemodynamically unstable
Answer:
IV conjugated equine estrogens in combinations with surgical options
uterine curettage - diagnostic and therapeutic effect
uterine tamponade
hysterectomy - last result
endometrial ablation - also r/o malignancy
Question:
menorrhagia: TX
Answer:
low dose COC - one pill BID x 5-7 days - should slow or stop bleeding within
first or second day of tx
after BID regimen continue until pack is empty or refill if desired
Update ) Primary Care
Adult Woman I | Questions &
Answers | Grade A | 100% Correct -
Regis
Question:
Lysteda (TXA) dose
Answer:
650mg 2 tabs BID x 5 days during menses
Question:
Lysteda when to prescribe
Answer:
when other options have been unsuccessful to tx menorrhagia in patients who
are not at high risk for thrombosis
,Question:
lysteda mechanism of action
Answer:
antifibrinolytic effect by blocking lysine bindings sites on plasminogen to
prevent fibrin degradation
Question:
menorrhagia: clinical manifestations
Answer:
bleeding more than 80ml/cycle, or cycle lasting longer than 7 days
Question:
menorrhagia: differential dx
Answer:
pregnancy, cervical abnormalities, uterine abnormalities, endometriosis,
medications, endocrine, foreign body
,Question:
menorrhagia: diagnostic wu
Answer:
UPT, cbc, std, pap, endometrial biopsy
depending on sxs
TSH
PTT, PT
Factor VIII
Von Willebrand
DHEA-S
testosterone
US
hysteroscopy
prolactin
Question:
menorrhagia: endometrial biopsy
Answer:
for all women > 45 OR AUB and other associated risk factors (unopposed
estrogen exposure, failed medical management of bleeding)
, Question:
menorrhagia: tx for hemodynamically unstable
Answer:
IV conjugated equine estrogens in combinations with surgical options
uterine curettage - diagnostic and therapeutic effect
uterine tamponade
hysterectomy - last result
endometrial ablation - also r/o malignancy
Question:
menorrhagia: TX
Answer:
low dose COC - one pill BID x 5-7 days - should slow or stop bleeding within
first or second day of tx
after BID regimen continue until pack is empty or refill if desired
